On Sunday, July 7, 2024, we exhibited at the Institute for Predictable Osseointegration in Implantology (IPOI), a non-profit organization (NPO) event held in Fukuoka City.
Read more
Mediplus Pharma, Inc. presented the safety and efficacy of its proprietary ingredient, ozonized glycerin (Novel Glycerin Compound), in formulations for atopic dermatitis at the 123rd Annual Meeting of the Japanese Dermatological Association. The conference was held from June 6 to June 9, 2024, at the Kyoto International Conference Center.
For more details on the press release, please visit here.
https://prtimes.jp/main/html/rd/p/000000015.000079724.html
Mediplus Pharma, Inc. (CEO: Kenji Ito, HQ: Shibuya, Tokyo) presented on the multifunctionality and application of its proprietary ingredient, ozonized glycerin (Novel Glycerin Compound), as biomaterials at the 12th World Biomaterials Congress (WBC), held over six days from May 26 to 31, 2024, in Daegu, South Korea.
For more details on the press release, please visit here.
https://prtimes.jp/main/html/rd/p/000000013.000079724.html
We are pleased to announce our participation in the 16th Academic Conference of the Non-Profit Organization (NPO) Institute for Predictable Osseointegration in Implantology, which will be held on Sunday, July 7, 2024, in Fukuoka City.
We aim to introduce our unique ingredient , ozonized glycerin, which is expected to have beneficial effects in dental medicine, particularly in the surgical field. This event will be an opportunity for dental professionals, especially those active in the surgical domain, to learn about our product.
At our exhibition booth, attendees will be able to experience ozonized glycerin and deepen their understanding through explanations from the developers.
